Brawn Biotech Ltd Stock Price Today (NSE: BRAWN)
Fundamental Score
Brawn Biotech Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Brawn Biotech Ltd share price today is ₹21.05, up +0.00% on NSE/BSE as of 23 June 2026. Brawn Biotech Ltd (BRAWN) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹5.78 (Cr). The 52-week high for BRAWN share price is ₹24.37 and the 52-week low is ₹16.16. The company has a Return on Equity (ROE) of -41.33% and a debt-to-equity ratio of 0.00.
Brawn Biotech Ltd Share Price Chart — NSE/BSE Historical Performance
Brawn Biotech Ltd share price chart: -7.87% return over the past month. 52-week high ₹24.37, 52-week low ₹16.16.
Brawn Biotech Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹21.05 | ₹21.05 | ₹21.05 | ₹21.05 | 20.00 (Cr) | |
| ₹21.50 | ₹21.55 | ₹21.05 | ₹21.05 | 465.00 (Cr) | |
| ₹20.75 | ₹20.75 | ₹20.75 | ₹20.75 | 108.00 (Cr) | |
| ₹20.13 | ₹20.13 | ₹20.13 | ₹20.13 | 0.00 (Cr) | |
| ₹20.13 | ₹20.13 | ₹20.13 | ₹20.13 | 0.00 (Cr) | |
| ₹20.13 | ₹20.13 | ₹20.13 | ₹20.13 | 0.00 (Cr) | |
| ₹20.50 | ₹20.50 | ₹20.13 | ₹20.13 | 122.00 (Cr) | |
| ₹20.55 | ₹20.55 | ₹20.55 | ₹20.55 | 333.00 (Cr) | |
| ₹21.60 | ₹21.60 | ₹21.60 | ₹21.60 | 36.00 (Cr) | |
| ₹21.60 | ₹21.60 | ₹21.60 | ₹21.60 | 11.00 (Cr) |
Brawn Biotech Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹21.50 | ₹21.55 | ₹21.05 | ₹21.05 | -2.09% | |
| ₹20.80 | ₹21.60 | ₹19.58 | ₹20.75 | -0.24% | |
| ₹19.85 | ₹23.49 | ₹18.54 | ₹20.80 | +4.79% | |
| ₹23.36 | ₹23.36 | ₹18.24 | ₹20.85 | -10.74% | |
| ₹21.16 | ₹22.60 | ₹17.71 | ₹22.25 | +5.15% | |
| ₹20.50 | ₹23.99 | ₹19.75 | ₹21.16 | +3.22% | |
| ₹19.26 | ₹23.08 | ₹19.12 | ₹21.51 | +11.68% | |
| ₹20.11 | ₹24.37 | ₹19.12 | ₹20.26 | +0.75% | |
| ₹22.10 | ₹23.20 | ₹19.11 | ₹21.10 | -4.52% | |
| ₹23.40 | ₹23.88 | ₹18.92 | ₹21.06 | -10.00% | |
| ₹19.99 | ₹23.96 | ₹16.66 | ₹23.40 | +17.06% | |
| ₹18.35 | ₹20.15 | ₹17.07 | ₹19.11 | +4.14% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Brawn Biotech Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Brawn Biotech Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of BRAWN across key market metrics for learning purposes.
Positive Indicators
5 factors identified
Robust Profit Growth (120.59%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (48.18%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Balanced Promoter Holding (53.66%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
6 factors identified
Below-Average Return on Equity (-41.33%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (-42.52%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Margin Pressure Concerns (-6.41%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
Limited Growth History (-22.97% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Limited Institutional Interest (FII+DII: 0.35%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Brawn Biotech Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Brawn Biotech Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Brawn Biotech LtdBrawn Biotech L...Selected✓ BRAWN • 530207 | 28/100 | ₹21.05₹21 | ₹5.78₹5.78 | — — | -41.33%Poor -41.33% Poor | -42.52%Poor -42.52% Poor | 0.00Excellent 0.0 Excellent | — — | -22.97%Poor -22.97% Poor | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1844.30₹1844 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6797.50₹6798 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4537.80₹4538 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1418.20₹1418 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1319.00₹1319 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2276.40₹2276 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2420.40₹2420 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1435.90₹1436 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5451.50₹5452 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Brawn Biotech Ltd Quarterly Performance
Latest quarterly metrics for BRAWN — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
48.18%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
120.59%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
-22.97%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
N/A
Compounded annual net profit growth over 5 years
Brawn Biotech Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for BRAWN — calculated from daily price history
Selling pressure is heavy — potential reversal zone.
Technical indicators are for educational purposes only. Not investment advice.
Brawn Biotech Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Brawn Biotech Ltd (BRAWN) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Brawn Biotech Ltd
About BRAWN (Brawn Biotech Ltd)
Brawn Biotech Ltd is a dynamic pharmaceutical company deeply rooted in the Indian healthcare landscape. Established in 1985 and headquartered in New Delhi, Brawn Biotech has evolve...d to become a significant player in the trading and distribution of a diverse range of pharmaceutical products. The company operates with a commitment to providing accessible and affordable healthcare solutions across various therapeutic areas. Brawn Biotech's portfolio is carefully curated to address the prevalent health needs of the Indian population, ensuring that essential medications reach those who need them most. Through strategic partnerships and a robust distribution network, Brawn Biotech diligently works to strengthen its presence and impact in the ever-evolving pharmaceutical sector. Brawn Biotech distinguishes itself by offering a comprehensive spectrum of pharmaceutical formulations designed to tackle a multitude of health challenges. Their product line encompasses critical medications addressing widespread ailments, including antibacterial agents to combat infections, cardiovascular drugs for heart health, and antidiabetic medications for managing diabetes. Furthermore, Brawn Biotech provides solutions for pain relief with their range of analgesics, digestive health through gastrointestinal formulations, and dermatological well-being with specialized skin care products. The company also caters to mental health with antipsychotic drugs, respiratory conditions with antiasthmatic medications, and offers relief from digestive discomfort with antacids. Brawn Biotech further contributes to public health by providing antimalarial drugs and essential nutritional products. Brawn Biotech operates with a forward-thinking approach, consistently adapting to the changing dynamics of the pharmaceutical industry. The company's commitment to quality and accessibility is reflected in its extensive product range and its dedication to reaching diverse patient populations. Formerly known as Brawn Pharmaceuticals Limited, the strategic name change to Brawn Biotech Limited in 2010 signaled a broader vision and a renewed focus on innovation and growth. With decades of experience in the Indian pharmaceutical market, Brawn Biotech is poised to further expand its reach and contribute to improving the health and well-being of communities across the nation.
Company Details
Key Leadership
Corporate Events
Latest News
BRAWN Share Price: Frequently Asked Questions
What is the current share price of Brawn Biotech Ltd?
Brawn Biotech Ltd (BRAWN) trades at ₹21.05 on NSE and BSE. Market cap ₹5.78 (Cr). Educational data only.
What is the P/E ratio of Brawn Biotech Ltd?
Brawn Biotech Ltd has a P/E of N/Ax vs industry average 31.77x.
What is the Bull Run score for Brawn Biotech Ltd?
Brawn Biotech Ltd has a Bull Run score of 28/100 based on 25+ financial parameters.
Does Brawn Biotech Ltd pay dividends?
Brawn Biotech Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Brawn Biotech Ltd?
Brawn Biotech Ltd has ROE of -41.33%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Brawn Biotech Ltd?
Brawn Biotech Ltd has debt-to-equity of 0.00.
Is Brawn Biotech Ltd a good investment?
Bull Run gives Brawn Biotech Ltd a score of 28/100. This is not investment advice — consult a SEBI-registered advisor.